Streetwise Reports: The Gold Report, The Energy Report, The Life Sciences Report and Streetwise Reports
755 Baywood Dr, Second Floor
Petaluma, CA 94954
(707) 981-8999 ext: 327
Streetwise Reports: The Gold Report, The Energy Report, The Life Sciences Report and Streetwise Reports are free publications of Streetwise Reports. If you would like to subscribe, please complete our online form.
Interested in becoming a sponsor or an Advertiser?
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
|"DRRX confirmed that it expects to complete patient follow-up visits this quarter, and announce top-line results from the Phase 3 PERSIST study in 4Q17."|
|"We believe that VIVE is currently in discussion with the agency and that a formal IDE would be submitted in the coming months such that a study (VIVEVE II) would commence in late 2017."|
|"We have recently performed additional diligence on INO's REVEAL and believe the program is well-designed to demonstrate clinically meaningful results which highlight potential advantages over surgery."|
|"On the back of DRRX's solid deal with Sandoz and with more catalysts to come in 2017 such as Posimir Phase 3 readout in 4Q17 and IND filings for DUR-928, we see potential near-term upside."|
|"We believe VIVE's Phase 3 trial is on track for a readout of data in mid-2019."|